As of June 30, 2025, MBX Biosciences (MBX) had cash, cash equivalents and marketable securities of $224.9 million. Based on its current operating plan, management expects the combined cash, cash equivalents and marketable securities balance to fund operations into mid-2027.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MBX:
- Block downgraded, Wayfair upgraded: Wall Street’s top analyst calls
- MBX Biosciences initiated with an Outperform at Mizuho
- Arm, Palantir upgraded: Wall Street’s top analyst calls
- MBX Biosciences initiated with an Outperform at Oppenheimer
- MBX Biosciences appoints Andreas Moraitis as SVP, clinical development